Young-onset biliary tract cancers: Characteristics, treatment patterns, and patient outcomes

The study underscores the scientific justification for investigating age-related differences in biliary tract cancers, revealing that patients with young-onset biliary tract cancer have improved survival outcomes and a higher prevalence of actionable molecular alterations, particularly <i>FGFR2</i> fusions. Physicians can apply these results by incorporating molecular profiling and targeted therapies earlier in the treatment plan for younger patients, potentially improving their prognosis and quality of life. However, it is crucial to consider the study's limitations, such as the retrospective design and potential selection bias, to avoid overgeneralization and ensure appropriate application of the findings in clinical practice and future research.

Authors

Institutions

Publication Details

Journal
JHEP Reports
Published
2025-08-11
DOI
https://doi.org/10.1016/j.jhepr.2025.101550
Primary Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Young-onset biliary tract cancers: Characteristics, treatment patterns, and patient outcomes

Marc Hilmi, D. López-Valbuena, T. Anthony, Tian V. Tian et al.
1 links
JHEP Reports
Cholangiocarcinoma and Gallbladder Cancer Studies
article

Young-onset biliary tract cancers: Characteristics, treatment patterns, and patient outcomes

Marc Hilmi, D. López-Valbuena, T. Anthony, Tian V. Tian, Leony Antoun, T. Pudlarz, Robine Adrien, C. Gloria, Michel Ducreux, Teresa Macarulla, Valérie Boige, A. Tarabay, H. Antoine, David Malka, S. Cristina, Shaposhnikova Natalia, Antoine Italiano, Castet Florián, Maximiliano Gelli, Valéry Marine, García-Galea Eduardo, Boilève Alice, Matthieu Delaye
article en

Abstract

The study underscores the scientific justification for investigating age-related differences in biliary tract cancers, revealing that patients with young-onset biliary tract cancer have improved survival outcomes and a higher prevalence of actionable molecular alterations, particularly <i>FGFR2</i> fusions. Physicians can apply these results by incorporating molecular profiling and targeted therapies earlier in the treatment plan for younger patients, potentially improving their prognosis and quality of life. However, it is crucial to consider the study's limitations, such as the retrospective design and potential selection bias, to avoid overgeneralization and ensure appropriate application of the findings in clinical practice and future research.

JHEP ReportsVol. 7(11)
Memorial Sloan Kettering Cancer Center (US), Université de Bordeaux (FR), Inserm (FR), Université de Lille (FR), Université Paris-Saclay (FR), Institut Gustave Roussy (FR), Centre Hospitalier Universitaire de Lille (FR), Lille’s Cardiology Hospital (FR), Institute Mutualiste Montsouris (FR), Vall d'Hebron Hospital Universitari (ES), Institut Bergonié (FR)
Good health and well-being
Openalex Percentile: Top 66%
Cholangiocarcinoma and Gallbladder Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.